What are the indications, dosing regimen, and monitoring recommendations for granulocyte colony‑stimulating factor (G‑CSF, e.g., filgrastim) in patients with myelodysplastic syndrome (MDS)?

G-CSF Use in Myelodysplastic Syndrome

G-CSF (filgrastim) can be used in MDS patients primarily for symptomatic neutropenia (ANC <1.5 × 10⁹/L) to reduce infection risk, but should be avoided during concurrent chemotherapy and radiation therapy, and used cautiously given theoretical concerns about blast stimulation.

Primary Indication: Symptomatic Neutropenia

G-CSF is indicated for MDS patients with neutropenia, particularly those with:

• Absolute neutrophil count (ANC) <1.5 × 10⁹/L 1, 2
• Recurrent infections or high infection risk
• Lower-risk MDS subtypes (RA, RARS, RAEB) where the goal is supportive care rather than disease modification

The most recent NCCN MDS guidelines (2025) recommend considering G-CSF in combination with erythropoiesis-stimulating agents (ESAs) for patients with lower-risk MDS and symptomatic anemia, particularly when serum EPO levels are ≤500 mU/mL 3.

Dosing Regimen

Standard dosing for MDS:

• Filgrastim: 0.5-2 mcg/kg/day subcutaneously 1, 2
• Start with 0.5 mcg/kg/day for 2 weeks; if no response, escalate to 1-2 mcg/kg/day 1
• Continue until ANC reaches >1.5 × 10⁹/L or normalizes
• Can be used as maintenance therapy with daily or alternate-day dosing for sustained benefit 4

This differs from the higher doses (5 mcg/kg/day) used in chemotherapy-induced neutropenia 5. The lower doses in MDS reflect the goal of supporting baseline hematopoiesis rather than recovering from acute myelosuppression.

Expected Response and Efficacy

Neutrophil response rates:

• 80-90% of MDS patients respond with 2-40 fold increases in ANC 1, 4, 2
• Response occurs across all baseline ANC levels (<0.5,0.5-1.0,1.0-1.5 × 10⁹/L) with similar efficacy (70-88% response rates) 1
• Median time to neutrophil recovery: 23 days when used with chemotherapy 6

Additional benefits:

• Decreased infection risk when ANC maintained >1.5 × 10⁹/L 4
• Improved bone marrow myeloid maturation in 70-80% of patients 4, 2
• Occasional improvement in anemia (20% rise in hematocrit or decreased transfusion requirements in 20-30% of patients) 4, 2
• No significant effect on platelet counts 1, 2

Critical Safety Considerations and Monitoring

Theoretical Risk of Blast Stimulation

The major concern with G-CSF in MDS is potential stimulation of leukemic blasts. While older studies showed G-CSF could induce differentiation of abnormal clones without accelerating leukemic transformation 2, more recent data raise concerns:

• Avoid in patients with excess blasts or high-risk MDS features
• Monitor blast counts closely during treatment
• If persistent leukemia after chemotherapy, stop G-CSF for several days to distinguish drug resistance from G-CSF stimulation 7
• Three patients progressed to AML during maintenance G-CSF therapy in one study 4

Absolute Contraindications

Do NOT use G-CSF in MDS patients receiving:

• Concurrent chemotherapy and radiation therapy (especially mediastinal radiation) due to increased bone marrow suppression, complications, and death risk 8, 7

Long-term Leukemia Risk

There is a possible increased risk of secondary AML/MDS in patients receiving G-CSF, though this is confounded by higher chemotherapy doses. In breast cancer patients, the absolute risk increase is very low (1.8% vs 0.7% at 48 months) 8. A 2022 study showed 10-year cumulative risk difference of only 0.45% in breast cancer and 0.39% in lung cancer 9.

Monitoring Recommendations

During G-CSF therapy:

• CBC with differential at least weekly initially, then every 2-4 weeks during maintenance
• Bone marrow examination if clinical deterioration or rising blast counts
• Monitor for infections despite improved ANC
• Assess response at 2 weeks; if inadequate, escalate dose 1
• Stop G-CSF if ANC >20 × 10⁹/L or reduce dose by 50% 7

Special Populations and Contexts

Use with Chemotherapy in Higher-Risk MDS

When G-CSF is combined with chemotherapy (e.g., CHG regimen: cytarabine + homoharringtonine + G-CSF):

• Complete remission rates: 47-73% in advanced MDS 10, 6, 11
• G-CSF given during and after chemotherapy (days 0-14, interrupted if WBC >20 × 10⁹/L) 10
• Accelerates neutrophil recovery (23 vs 35 days) but doesn't reduce infection complications 6
• Well-tolerated with mild-to-moderate myelosuppression 10

Combination with ESAs

The NCCN guidelines recommend considering G-CSF + ESAs for lower-risk MDS patients with:

• Serum EPO ≤500 mU/mL
• Symptomatic anemia
• No response to ESAs alone after 6-8 weeks 3

Practical Algorithm for G-CSF Use in MDS

Step 1: Assess eligibility

• Lower-risk MDS (RA, RARS, RAEB with <10% blasts)
• ANC <1.5 × 10⁹/L
• Recurrent infections or high infection risk
• NOT receiving concurrent chemoradiation

Step 2: Initiate therapy

• Start filgrastim 0.5 mcg/kg/day subcutaneously
• Monitor CBC weekly

Step 3: Assess response at 2 weeks

• If ANC >1.5 × 10⁹/L: continue current dose
• If inadequate response: escalate to 1-2 mcg/kg/day

Step 4: Maintenance

• Continue daily or alternate-day dosing
• Monitor CBC every 2-4 weeks
• Bone marrow exam every 3-6 months or if clinical deterioration

Step 5: Discontinue if:

• Progression to AML
• Rising blast counts
• Persistent ANC >20 × 10⁹/L despite dose reduction
• No benefit after 4 weeks at maximum dose

Key Pitfalls to Avoid

1. Using standard chemotherapy doses (5 mcg/kg/day) instead of lower MDS-specific doses (0.5-2 mcg/kg/day)
2. Continuing G-CSF during concurrent chemoradiation (associated with increased mortality)
3. Failing to monitor blast counts during therapy
4. Using in high-risk MDS with excess blasts without careful consideration
5. Expecting platelet or hemoglobin improvements as primary endpoints (these are inconsistent benefits)